Diffuse Large B-Cell Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 70+ Companies and 75+ Therapies
DelveInsight's, ' Diffuse Large B-Cell Lymphoma Pipeline Insight 2025 ' report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in Diffuse Large B-Cell Lymphoma pipeline landscape. It covers the Diffuse Large B-Cell Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Diffuse Large B-Cell Lymphoma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive Diffuse Large B-Cell Lymphoma pipeline products in this space.
Stay ahead with the latest insights! Download DelveInsight's comprehensive Diffuse Large B-Cell Lymphoma Pipeline Report to explore emerging therapies, key Diffuse Large B-Cell Lymphoma Companies, and future Diffuse Large B-Cell Lymphoma treatment landscapes @ Diffuse Large B-Cell Lymphoma Pipeline Outlook Report
Key Takeaways from the Diffuse Large B-Cell Lymphoma Pipeline Report
In June 2025, Genmab announced a study will assess how safe and effective epcoritamab plus lenalidomide (E-Len) is compared to rituximab plus gemcitabine and oxaliplatin (R-GemOx) )in treating adult participants with relapsed or refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL). Adverse events and change in disease condition will be assessed.
In June 2025, Mitsubishi Tanabe Pharma Corporation conducted a phase I/II Open-Label Study of MT-2111 in Patients With Relapsed/Refractory DLBCL.
DelveInsight's Diffuse Large B-Cell Lymphoma pipeline report depicts a robust space with 70+ active players working to develop 75+ pipeline therapies for Diffuse Large B-Cell Lymphoma treatment.
The leading Diffuse Large B-Cell Lymphoma Companies such as Miltenyi Biomedicine, Adicet Bio, VelosBio, Novartis Pharmaceuticals, Sanofi, Eisai Co, Schrodinger, Sana Biotechnology, Ranok Therapeutics, Monte Rosa Therapeutic, Otsuka Pharmaceutical, OncoNano Medicine, Regeneron Pharmaceuticals, Hoffmann-La Roche, Celgene, Nurix Therapeutics, NovalGen, Nektar Therapeutics, Genentech, CSPC ZhongQi Pharmaceutical Technology and others.
Promising Diffuse Large B-Cell Lymphoma Therapies such as Ibrutinib, Bendamustine, Rituximab, R-miniCHOP, Selinexor, Tafasitamab, Lenalidomide, and others.
Discover how the Diffuse Large B-Cell Lymphoma treatment paradigm is evolving. Access DelveInsight's in-depth Diffuse Large B-Cell Lymphoma Pipeline Analysis for a closer look at promising breakthroughs @ Diffuse Large B-Cell Lymphoma Clinical Trials and Studies
Diffuse Large B-Cell Lymphoma Emerging Drugs Profile
Brentuximab vedotin: Pfizer
Brentuximab vedotin (Adcetris) is an anti-neoplastic agent. It is indicated for the treatment of patients with Classical Hodgkin lymphoma (HL) after failure of autologous hematopoietic stem cell transplantation (auto-HSCT) or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not auto-HSCT candidates. Adcetris is also indicated for the treatment of adult patients with CD30+ Hodgkin lymphoma at increased risk of relapse or progression following autologous stem cell transplant (ASCT), also indicated for the treatment of adult patients with relapsed or refractory systemic anaplastic large cell lymphoma, for the treatment of adult patients with primary cutaneous anaplastic large cell lymphoma (pcALCL) and CD30-expressing mycosis fungoides (MF) who have received prior systemic therapy, for the treatment of adult patients with relapsed or refractory CD30+ cutaneous T- cell lymphoma (CTCL) after at least 1 prior systemic therapy. Adcetris is indicated for the first-line pediatric treatment for CD30-positive Hodgkin lymphoma. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Diffuse Large B Cell Lymphoma.
THOR-707: Sanofi
THOR-707 is a precisely PEGylated version of IL-2, where the PEG chain is attached to a novel amino acid inserted at a location on IL-2 that prevents it from engaging the alpha-receptor and binding to immune receptors that cause drug toxicities (IL-2R-alpha, CD25). The engineered IL-2 retains near-native binding to the beta-gamma receptors that selectively expand tumor-killing T effector cells and Natural Killer (NK) cells without the alpha-mediated immunosuppressive effects of regulatory T cells or eosinophil-mediated vascular leak syndrome. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Diffuse Large B Cell Lymphoma.
Abexinostat: Xynomic Pharmaceuticals
Abexinostat (Xynomic Pharmaceuticals) is a broad histone deacetylase (HDAC) inhibitor. HDAC enzymes (also known as lysine deacetylase) cleave acetyl groups from N-acetyl lysine amino acids on a histone. HDAC inhibition leads to highly acetylated histones and chromatin reshaping. In addition to altering histone acetylation, HDAC inhibitors can also influence the degree of acetylation on non-histone proteins, increasing or repressing their activity. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Diffuse Large B-cell lymphoma.
RNK05047: Ranok Therapeutics
RNK05047 is a first-in-class, small-molecule, tumor- and BRD4-selective protein degrader that was discovered and developed using Ranok's proprietary approach to targeted protein degradation, CHAMPTM. The bromodomain transcription factor BRD4 is a key regulator of oncogenes such as MYC and BCL2 and is involved in diverse cancer types. CHAMP-1 is a Phase I/II trial of RNK05047 currently underway in the US that will assess its safety, tolerability, and pharmacokinetics, and also includes measures of anti-tumor activity and pharmacodynamics readouts as secondary endpoints.
BMF-219: Biomea Fusion
BMF-219 is an oral investigational covalent menin inhibitor. Data suggests that optimized covalent inhibitors can provide deeper inhibition while being better tolerated than some conventional reversible inhibitors. BMF-219 is being developed for genetically defined AML, ALL, DLBCL, MM and CLL patients. BMF-219 blocks the interaction of menin and MLL (AML, ALL), and limits the activity and/or expression of NPM1, MYC, HOX, and MEIS1, all known drivers of oncogenic proliferation and survival. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Diffuse Large B Cell Lymphoma.
ADI-001: Adicet Bio
ADI-001 is an investigational allogeneic gamma delta CAR T cell therapy being developed as a potential treatment for relapsed or refractory B-cell NHL. ADI-001 targets malignant B-cells via an anti-CD20 CAR and via the gamma delta innate and T cell endogenous cytotoxicity receptors. Gamma delta T cells engineered with an anti-CD20 CAR have demonstrated potent anti-tumor activity in preclinical models, leading to long-term control of tumor growth. In April 2022, ADI-001 was granted Fast Track Designation by the FDA for the potential treatment of relapsed or refractory B-cell NHL. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Diffuse Large B Cell Lymphoma.
The Diffuse Large B-Cell Lymphoma pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Diffuse Large B-Cell Lymphoma with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Diffuse Large B-Cell Lymphoma Treatment.
Diffuse Large B-Cell Lymphoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Diffuse Large B-Cell Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Diffuse Large B-Cell Lymphoma market.
Get a detailed analysis of the latest innovations in the Diffuse Large B-Cell Lymphoma pipeline. Explore DelveInsight's expert-driven report today! @ Diffuse Large B-Cell Lymphoma Unmet Needs
Diffuse Large B-Cell Lymphoma Companies
Miltenyi Biomedicine, Adicet Bio, VelosBio, Novartis Pharmaceuticals, Sanofi, Eisai Co, Schrodinger, Sana Biotechnology, Ranok Therapeutics, Monte Rosa Therapeutic, Otsuka Pharmaceutical, OncoNano Medicine, Regeneron Pharmaceuticals, Hoffmann-La Roche, Celgene, Nurix Therapeutics, NovalGen, Nektar Therapeutics, Genentech, CSPC ZhongQi Pharmaceutical Technology and others.
Diffuse Large B-Cell Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Oral
Intravenous
Subcutaneous
Parenteral
Topical
Diffuse Large B-Cell Lymphoma Products have been categorized under various Molecule types such as
Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy
Download DelveInsight's latest report to gain strategic insights into upcoming Diffuse Large B-Cell Lymphoma Therapies and key Diffuse Large B-Cell Lymphoma Developments @ Diffuse Large B-Cell Lymphoma Market Drivers and Barriers, and Future Perspectives
Scope of the Diffuse Large B-Cell Lymphoma Pipeline Report
Coverage- Global
Diffuse Large B-Cell Lymphoma Companies- Miltenyi Biomedicine, Adicet Bio, VelosBio, Novartis Pharmaceuticals, Sanofi, Eisai Co, Schrodinger, Sana Biotechnology, Ranok Therapeutics, Monte Rosa Therapeutic, Otsuka Pharmaceutical, OncoNano Medicine, Regeneron Pharmaceuticals, Hoffmann-La Roche, Celgene, Nurix Therapeutics, NovalGen, Nektar Therapeutics, Genentech, CSPC ZhongQi Pharmaceutical Technology and others.
Diffuse Large B-Cell Lymphoma Therapies - Ibrutinib, Bendamustine, Rituximab, R-miniCHOP, Selinexor, Tafasitamab, Lenalidomide, and others.
Diffuse Large B-Cell Lymphoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Diffuse Large B-Cell Lymphoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Which companies are leading the race in Diffuse Large B-Cell Lymphoma drug development? Find out in DelveInsight's exclusive Diffuse Large B-Cell Lymphoma Pipeline Report—access it now! @ Diffuse Large B-Cell Lymphoma Emerging Drugs and Major Companies
Table of Content
Introduction
Executive Summary
Diffuse Large B-Cell Lymphoma: Overview
Pipeline Therapeutics
Therapeutic Assessment
Diffuse Large B-Cell Lymphoma– DelveInsight's Analytical Perspective
Late Stage Products (Phase III)
Brentuximab vedotin: Pfizer
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
THOR-707: Sanofi
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
ADI-001: Adicet Bio
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug name: Company name
Drug profiles in the detailed report…..
Inactive Products
Diffuse Large B-Cell Lymphoma Key Companies
Diffuse Large B-Cell Lymphoma Key Products
Diffuse Large B-Cell Lymphoma- Unmet Needs
Diffuse Large B-Cell Lymphoma- Market Drivers and Barriers
Diffuse Large B-Cell Lymphoma- Future Perspectives and Conclusion
Diffuse Large B-Cell Lymphoma Analyst Views
Diffuse Large B-Cell Lymphoma Key Companies
Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/diffuse-large-b-cell-lymphoma-pipeline-insight
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
3 hours ago
- Globe and Mail
Identity Security Posture Management Market: Growing Trends, Future Outlook, Advance Technology And Forecast
"Microsoft (US), Cisco (US), Oracle (US), Palo Alto Networks (US), CrowdStrike (US), Check Point (US), Okta (US), Trend Micro (Japan), CyberArk (US), Ping Identity (US), SailPoint (US), BeyondTrust (US), ManageEngine (US), Mesh Security (US), Delinea (US), Silverfort (Israel), Veza (US), One Identity (US)." Identity Security Posture Management (ISPM) Market Size, Share, Growth Analysis, By Offering (Solutions, Services), Deployment Mode (On-premises, Cloud), Organization Size, Vertical and Region - Global Industry Forecast to 2029. The identity security posture management (ISPM) market is expected to reach a value of USD 33.1 billion by 2029, up from USD 13.7 billion in 2024, at a Compound Annual Growth Rate (CAGR) of 19.3%. The move to cloud services is driving the growth of the ISPM market by increasing the requirement for secure identity management in cloud environments and increasing the risk of identity-based threats. Identity security must be approached holistically due to the increasing complexity of cyberthreats. The adoption of ISPM solutions is being driven by the need for organizations to actively maintain and improve their security measures to protect against breaches and unauthorized entry, as hackers employ increasingly complex techniques to exploit identity weaknesses. Download PDF Brochure@ ISPM solutions enable organizations to unify and streamline identity governance across diverse environments, providing granular access controls, continuous monitoring, and automated responses to security incidents. By addressing these complexities, ISPM solutions bolster resilience against cyber threats, enhance compliance with industry regulations, and safeguard critical assets in today's interconnected digital landscape. Based on the offering, the solutions segment accounts for the highest market size during the forecast period. The adoption of ISPM solutions is driven by the increasing recognition of identity-related vulnerabilities as the weakest link in cybersecurity. Also, the adoption is driven by integrating AI and machine learning for proactive threat detection, the rise of remote work and BYOD policies, and the complexity of managing identities across hybrid IT environments, which underscore the need for robust ISPM solutions. These technologies enable organizations to achieve comprehensive visibility, enforce least privilege access, and automate identity governance, strengthening overall security posture and resilience against evolving cyber threats. By deployment mode, the cloud segment will grow at the highest CAGR during the forecasted period. The adoption of ISPM in cloud deployment mode is driven by the rapid migration of enterprise workloads to cloud environments, facilitated by trends such as digital transformation, remote workforces, and the scalability of cloud services. Organizations increasingly leverage ISPM cloud solutions to manage identities centrally and access across dispersed IT infrastructures, ensuring consistency, agility, and enhanced security. This approach allows for seamless integration with cloud-native identity services, robust API-based controls, and real-time monitoring capabilities, enabling businesses to mitigate risks effectively, comply with regulatory requirements, and optimize operational efficiencies in the evolving digital landscape. By region, Asia Pacific will grow at the highest CAGR during the forecast period. The Asia Pacific region comprises countries such as China, India, Australia, and Japan, leading in the ISPM market. Asia Pacific region is expected to register high growth rates in the ISPM market. China is the leading country in this market, with extensive adoption of ISPM technology in various sectors, including BFSI, government, and healthcare. Other countries in the region, such as Japan, are also witnessing growth in the ISPM market. The rapid digitalization of economies drives the ISPM growth, the increasing sophistication of cyber threats targeting businesses and government agencies, and the growing regulatory scrutiny around data protection and privacy laws. Also, there is a rising number of emerging startups in the region in the ISPM space. Request Sample Pages@ Unique Features in the Identity Security Posture Management Market ISPM solutions offer unified and continuous visibility into identity-related risks across hybrid and multi-cloud environments. They monitor identity configurations, permissions, entitlements, and behavior patterns to detect exposure points. This holistic view enables organizations to proactively address identity threats before they are exploited. A distinctive feature of ISPM is its ability to integrate seamlessly with existing IAM tools such as Single Sign-On (SSO), Privileged Access Management (PAM), and Identity Governance and Administration (IGA). This integration enables ISPM platforms to enrich data context, extend protection across the identity lifecycle, and improve identity hygiene. ISPM platforms use advanced analytics and AI/ML to assign risk scores to identities based on activity anomalies, overprivileged access, stale accounts, and policy violations. This helps security teams prioritize remediation efforts and focus on high-risk identities, ensuring efficient resource allocation. Unlike traditional periodic assessments, ISPM solutions perform real-time and continuous posture assessments, identifying misconfigurations and compliance gaps instantly. Automated policy enforcement ensures that security controls are consistently applied and deviations are corrected promptly. Major Highlights of the Identity Security Posture Management Market The ISPM market is witnessing significant growth due to the surge in identity-based cyberattacks, such as credential theft, lateral movement, and privilege escalation. Organizations are increasingly prioritizing identity security posture to defend against these advanced threats, especially in hybrid and cloud environments. With the widespread adoption of zero trust security frameworks, ISPM solutions have become essential in enforcing least privilege access and continuously validating identity posture. Enterprises are leveraging ISPM to align their identity and access controls with zero trust principles and reduce attack surfaces. The growing complexity of IT ecosystems, particularly due to the rise of multi-cloud and hybrid infrastructure, has fueled the demand for ISPM solutions. Organizations are seeking unified tools that provide centralized visibility and control over identity risks across disparate platforms and services. ISPM is increasingly being integrated with other cybersecurity solutions such as IAM, SIEM, SOAR, and Cloud Security Posture Management (CSPM). This convergence enables comprehensive risk detection and response capabilities, empowering security teams to act on identity threats faster and more effectively. Inquire Before Buying@ Top Companies in the Identity Security Posture Management Market Microsoft (US), Cisco (US), Oracle (US), Palo Alto Networks (US), CrowdStrike (US), Check Point (US), Okta (US), Trend Micro (Japan), CyberArk (US), Ping Identity (US), SailPoint (US), BeyondTrust (US), ManageEngine (US), Mesh Security (US), Delinea (US), Silverfort (Israel), Veza (US), One Identity (US), Radiant Logic (US), PlainID (Israel), Zilla Security (US), Adaptive Shield (Israel), AuthMind (US), Grip Security (Israel), Rezonate (US), and Sharelock (Italy) are the key players and other players in the ISPM market. CrowdStrike (US) is a leading cybersecurity company that protects endpoints, cloud workloads, identity, and data to stay ahead of current threats and prevent breaches. The company's main product, Falcon, utilizes artificial intelligence and machine learning to identify and stop cyber threats. The platform comprises EDR technology, threat-hunting abilities, and extensive threat intelligence. Furthermore, CrowdStrike provides an Identity Security and Protection Management (ISPM) module, which offers immediate visibility, detection, and defense against identity-focused attacks. Cisco (US) is a global networking and IT infrastructure leader renowned for its innovative connectivity, cybersecurity, and collaboration solutions. The company's comprehensive portfolio includes networking hardware, software, and services that support enterprises in their digital transformation journeys. Its Cisco is committed to driving technological advancements and providing robust security measures to protect digital assets. In August 2023, Cisco acquired Oort, a cybersecurity firm specializing in identity threat detection and response. This acquisition aims to enhance Cisco's security offerings by integrating Oort's advanced identity security capabilities, enabling more effective protection against identity-based threats and reinforcing Cisco's position as a leader in the cybersecurity industry. The company has a global presence in North America, Europe, Middle East & Africa, Asia Pacific, and Latin America. According to MnM's approach to evaluating the market, most businesses use inorganic growth tactics to hold onto their market share. These agreements cover alliances, acquisitions, collaborations, and partnerships together. Product launches and corporate growth activities are abruptly affected by factors such as government regulations. On the other hand, organizations are anticipated to embrace organic growth strategies to provide end consumers with ISPM solutions and professional services, which would assist businesses in boosting market revenue. Microsoft(US) is a major player in the Identity Security Posture Management (ISPM) market, offering solutions like Microsoft Entra and Defender for Identity to protect against identity-based threats. Its AI-driven security framework enhances access controls, detects anomalies, and strengthens zero-trust security for enterprises.
Globe and Mail
3 hours ago
- Globe and Mail
AI in Remote Patient Monitoring (RPM) Market worth $8,438.5 million by 2030 with 27.5% CAGR
"The AI in remote patient monitoring market is dominated by key players. The major players operating in this market are, Koninklijke Philips N.V. (Netherlands), Medtronic (Ireland), OMRON Helathcare, Inc. (Japan), GE HealthCare (US), Biobeat (Israel), Boston Scientific Corporation (US)" Browse 290 market data Tables and 59 Figures spread through 323 Pages and in-depth TOC on "AI in Remote Patient Monitoring (RPM) Market by Component (Device: Wearable, Implantable, Portable; Software, Service), Indication (Cardiac, Neuro, Onco, Diabetes, Sleep, Mental Health), End User (Hospitals, Clinics, Payer), Region - Global Forecast to 2030 The global AI in Remote Patient Monitoring Market, valued at US$1551.8 million in 2023, is forecasted to grow at a robust CAGR of 27.5%, reaching US$1967.7 million in 2024 and an impressive US$8438.5 million by 2030. The growing number of elderly people and the growing need for affordable healthcare solutions are the main factors propelling the AI in remote patient monitoring market. The United Nations Population Fund (UNFPA) predicts people aged 65 and older will grow from 10.3% worldwide population in 2024 to 20.7% by 2074. People aged 65+ will put a high strain on health services since healthcare budgets remain limited. Download PDF Brochure: Browse in-depth TOC on ' Artificial Intelligence in Remote Patient Monitoring Market' 290 - Tables 59 - Figures 323 - Pages By component, the artificial intelligence in remote patient monitoring market has been segmented into devices, software and services. In 2023, devices segment is estimated to hold the largest share of the market for AI in remote patient monitoring. AI-powered wearables like smartwatches and biosensors enable seamless, real-time health tracking, while portable and handheld devices such as AI-driven ECG monitors and glucose meters support remote diagnostics and chronic disease management. In the hospital environment, these stationary devices have helped increase the efficiency of Remote Patient Monitoring by functioning alongside enhanced AI analytics, cloud computing, and the Internet of Medical Things for optimum data transmission. As part of its continued commitment to telehealth and easily available, technologically enabled patient care, the Department of Veterans Affairs (VA) initiated several projects in 2025 to enhance remote patient monitoring (RPM). Among those were contracts to establish systems to allow tracking via telemetry for some 35 VA Medical Centers. By end-user, the global AI in remote patient monitoring market has seen significant growth at a very rapid pace. The patient segment is anticipated to be the biggest driver of growth in this sector. Factors such as the rising prevalence of chronic diseases, growing awareness of personalized healthcare, and increased patient engagement in self-monitoring are driving this growth. By enabling early disease detection, predictive analytics, and real-time monitoring of health, AI improves RPM, reduces hospital stays length, and recommends better patient outcomes. Real-time monitoring of health due to AI, predictive analytics, and early detection of diseases forms RPM to result in reduced hospital stay lengths and improved patient outcomes. AI-powered virtual assistants, digital health platforms, and remote diagnostics allow remote patient monitoring to become easier and more efficient, further boosting the growth of this market. An example is the KardiaRx App developed by AliveCor, Inc. that empowers patients and clinical trial participants to record ECGs at home. By geography, the artificial intelligence in remote patient monitoring market (RPM) is segmented into five major regions: North America, Asia Pacific, Europe, Middle East & Africa, and Latin America. Asia Pacific is expected to register highest growth during the forecast period. Factors which are driving this growth include increased in disposable incomes. Access to healthcare has changed significantly in this region, which is home to two-thirds of the world's population. This is particularly true in nations like China, where 10 million more seniors are added each. The region's governments have started programs to increase gadget manufacturing. India has invested 1,057.47 crore rupees as of September 2024 to construct 50 new manufacturing plants, while construction is underway on another 50. This endeavor is crucial to boosting the nation's ability to produce cutting-edge medical devices and facilitate the use of AI in remote patient monitoring. In order to provide everyone with access to reasonably priced and high-quality RPM and telehealth services, the National Digital Health Mission (NDHM) also seeks to establish a digital health ecosystem. Request Sample Pages: The AI in remote patient monitoring market is dominated by key players. The major players operating in this market are, Koninklijke Philips N.V. (Netherlands), Medtronic (Ireland), OMRON Helathcare, Inc. (Japan), GE HealthCare (US), Biobeat (Israel), Boston Scientific Corporation (US), Dexcom, Inc. (US), NIHON KOHDEN CORPORATION (Japan), F. Hoffmann-La Roche Ltd (Roche Diagnostics) (Switzerland), ResMed Inc. (US), AliveCor, Inc. (US), Biotronik (Germany), Beijing Choice Electronic Tech Co. Ltd. (China), TytoCare Ltd. (US), Gloooko, Inc. (US), Welldoc, Inc. (US), Zeto Inc. (US), Turtle Shell Technologies Pvt. Ltd. (Dozee) (India), Masimo (US), iRhythm Inc. (US). Koninklijke Philips N.V. (Netherlands): Koninklijke Philips N.V. is the parent company of the Philips Group. The company works in four areas: Personal Health, Diagnosis and Treatment, Connected Care and Others. Connected Care segments provide Al in Remote Patient Monitoring solutions. Philips has grown over time through collaborations with key partners in the marketplace. In July 2024, the organization partnered with Bon Secours Mercy Health on a short-term initiative that aimed to enhance patient monitoring within 49 hospitals. The objective was to raise care quality while maintaining costs under control. Some of its major subsidiaries are Philips Oral Healthcare, LLC (US), Philips GmbH (Germany), Philips Ultrasound, Inc. (US), and Philips Consumer Lifestyle B.V. (Netherlands). It spans operations across North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. Medtronic (Ireland): Medtronic is a global healthcare technology company based in Dublin, Ireland. The company helps healthcare systems, doctors, clinicians, and patients in more than 150 countries worldwide. It operates through four main business areas: Cardiovascular, Neuroscience, Medical Surgical, and Diabetes. Medtronic offers AI-powered Remote Patient Monitoring solutions across all four of its business segments. Also, approvals and partnerships are being pursued for an expansion of its diabetes device portfolio. In August 2024, Medtronic announced a partnership with Abbott for the integration of continuous glucose monitoring technology to improve diabetes care for the patients. In August 2024, Medtronic introduced the Simplera Continuous CGM and announced the intent for FDA and PMDA approval. The system offers secure near real-time glucose monitoring that helps users to realize better blood sugar control. Boston Scientific Corporation (US): Boston Scientific Corporation is a global developer, manufacturer, and marketer of medical devices used in a broad range of interventional medical specialties. The company operates primarily in two business segments, MedSurg and Cardiovascular. The MedSurg segment focuses on endoscopy, urology, and neuromodulation, offering minimally invasive solutions for various medical conditions. The Cardiovascular segment includes interventional cardiology, cardiac rhythm management, electrophysiology, and peripheral interventions, providing technologies for diagnosing and treating heart and vascular diseases. The company provides AI in remote patient monitoring through Cardiovascular segment. Boston Scientific operates in over 40 countries across six continents, with regional headquarters and offices in the North America, Europe, Asia Pacific, Latin America and Middle East and Africa For more information, Inquire Now!
Globe and Mail
6 hours ago
- Globe and Mail
Can New Nanosheet Chip Nodes Cement TSM's Long-Term Tech Leadership?
Taiwan Semiconductor Manufacturing Company TSM, also known as TSMC, is reinforcing its nanosheet chip technology roadmap with N2, N2P, and A16, which are aimed at extending performance and efficiency at advanced nodes. Out of these, the A16 advanced node has been specifically designed to accommodate high-performance computing (HPC) products and AI-class workloads. These advanced nodes are expected to extend TSMC's technology leadership position and enable it to capture growth opportunities into the future. Taiwan Semiconductor's N2 logic node is the first generation of nanosheet transistor technology and offers 10-15% speed improvement, 25-30% power improvement, and more than 15% chip density gain when compared with N3E. The logic node is on track to enter volume production in the second half of 2025. Moreover, TSMC also expects the number of new tape-outs for N2, fueled by both smartphone and HPC applications, to be higher than both 3-nanometer and 5-nanometer in their first two years. Taiwan Semiconductor is winning important customers, such as AMD and Apple, for its new N2 advanced logic node. Apple plans to use these chips in future iPhones and Mac devices, while AMD wants to use them to make faster CPUs and GPUs to compete better in the market. Introduced in the first quarter of 2025, N2P is an extension of the N2 family, which features improved performance and power efficiency. A16 is also a nanosheet-based technology with backside power delivery and is intended to be a logical upgrade to N2P. The A16 logic node, also introduced in the first quarter, is expected to deliver up to 15-20% power improvement and an additional 7-10% chip density gain when compared with N2P. With fabs under construction in Taiwan and Arizona to support both N2 and A16 and volume production scheduled for N2P and A16 in the second half of 2025, Taiwan Semiconductor appears well-positioned to benefit from the next wave of AI and high-performance computing demand. How Competitors Fare Against TSM Two key competitors, Intel INTC and GlobalFoundries GFS, are working hard to catch up with TSMC's lead. Intel plans to launch its 2nm-based node, called Intel 18A, in the second half of 2025. Intel is focusing on new technologies like RibbonFET transistors and backside power delivery for its 18A node, similar to TSMC's A16. Meanwhile, GlobalFoundries is not focused on 2nm chips. Instead, it is investing in specialized chips for cars, wireless devices, and the IoTs. While GlobalFoundries does not directly compete with Taiwan Semiconductor at the most advanced nodes, it still aims to take market share in fast-growing chip segments. TSM's Price Performance, Valuation and Estimates Shares of Taiwan Semiconductor have gained 9.7% year to date compared with the Semiconductor - Circuit Foundry industry's growth of 8.7%. TSM YTD Price Return Performance From a valuation standpoint, TSMC trades at a forward price-to-sales ratio of 9.08X, slightly higher than the industry's average of 9.02X. TSM Forward 12-Month P/S Ratio The Zacks Consensus Estimate for TSMC's 2025 and 2026 earnings implies year-over-year growth of 30.54% and 14.80%, respectively. The estimates for 2025 have been revised upward in the past 60 days, while the estimates for 2026 have witnessed a downward revision over the same time frame. TSMC currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. 7 Best Stocks for the Next 30 Days Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops." Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.5% per year. So be sure to give these hand picked 7 your immediate attention. See them now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Intel Corporation (INTC): Free Stock Analysis Report GlobalFoundries Inc. (GFS): Free Stock Analysis Report
